NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Core Insights - NKGen Biotech's troculeucel shows promise in reducing biomarkers associated with Alzheimer's Disease (AD), potentially delaying or preventing dementia onset in asymptomatic individuals [1][4][5] - Preliminary results from a Phase 1/2a trial indicate that troculeucel is safe and effective, with 100% of subjects showing stable or improved cognitive function after treatment [2][6] - The company presented findings at the 17th Clinical Trials on Alzheimer's Disease Annual Meeting, highlighting the potential of troculeucel as a treatment for moderate AD [3][8] Biomarker Analysis - Troculeucel reduces levels of GFAP, NfL, p-tau181, GDF-15, and LTBP2, which are detectable up to 10 years before dementia symptoms appear [1][4] - In a recent study, 70% of subjects showed improvement in p-Tau181, 60% in the AB42/40 ratio, and 30% in NF-L after treatment [7] - The analysis suggests that increased screening for these biomarkers in asymptomatic individuals could identify those at high risk for AD [5][7] Clinical Trial Results - In the Phase 1/2a trial, three subjects received the highest dose of 6 billion cells, with two showing clinical improvement from moderate to mild AD after three months [2][8] - The treatment was well-tolerated, with no adverse reactions reported, and 90% of evaluable subjects experienced stable or improved cognitive function [5][6] - The ongoing Phase 2a trial aims to confirm the efficacy of troculeucel in a larger, randomized cohort [6][8] Company Overview - NKGen Biotech is focused on developing innovative autologous and allogeneic natural killer cell therapeutics for neurodegenerative disorders and cancers [10][11] - Troculeucel, the company's lead product, is a patient-specific ex vivo expanded autologous NK cell immunotherapeutic drug candidate [10] - The World Health Organization has assigned the International Nonproprietary Name (INN) for troculeucel, marking a significant step towards commercialization [10]